Methods: To evaluate the effect of tofacitinib upon the immune response and safety of LZV, we recruited pts aged ≥50 years with active RA (≥4 tender/painful joints and ≥4 swollen joints) despite methotrexate (MTX) therapy (≥4 months of treatment with 15–25 mg/week [wk] before screening)...